Oncology Key lessons from EHA 2026: Translating evidence into impact Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.
News FDA hands BeOne, Taiho approvals for blood cancers BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.
News Kura scores FDA okay for rival to Syndax's leukaemia drug Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.
News Ipsen buys ImCheck, adding mid-stage leukaemia drug Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.
News Ignota vacuums up Kronos Bio's drug programmes Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.
News ASH: Stem cell transplant study exposes US zip-code lottery Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
